Literature DB >> 29408436

Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.

Laurens P Bosman1, Arjan Sammani2, Cynthia A James3, Julia Cadrin-Tourigny4, Hugh Calkins5, J Peter van Tintelen6, Richard N W Hauer7, Folkert W Asselbergs8, Anneline S J M Te Riele9.   

Abstract

While many studies evaluate predictors of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy (ARVC), a systematic review consolidating this evidence is currently lacking. Therefore, we searched MEDLINE and Embase for studies analyzing predictors of ventricular arrhythmias (sustained ventricular tachycardia/fibrillation (VT/VF), appropriate implantable cardioverter-defibrillator therapy, or sudden cardiac death) in patients with definite ARVC, patients with borderline ARVC, and ARVC-associated mutation carriers. In the case of multiple publications on the same cohort, the study with the largest population was included. This yielded 45 studies with a median cohort size of 70 patients (interquartile range 60 patients) and a median follow-up of 5.0 years (interquartile range 3.3 - 6.7 years). The average proportion of arrhythmic events observed was 10.6%/y in patients with definite ARVC, 10.0%/y in patients with borderline ARVC, and 3.7%/y with mutation carriers. Predictors of ventricular arrhythmias were population dependent: consistently predictive risk factors in patients with definite ARVC were male sex, syncope, T-wave inversion in lead >V3, right ventricular dysfunction, and prior (non)sustained VT/VF; in patients with borderline ARVC, 2 additional predictors-inducibility during electrophysiology study and strenuous exercise-were identified; and with mutation carriers, all aforementioned predictors as well as ventricular ectopy, multiple ARVC-related pathogenic mutations, left ventricular dysfunction, and palpitations/presyncope determined arrhythmic risk. Most evidence originated from small observational cohort studies, with a moderate quality of evidence. In conclusion, the average risk of ventricular arrhythmia ranged from 3.7 to 10.6%/y depending on the population with ARVC. Male sex, syncope, T-wave inversion in lead >V3, right ventricular dysfunction, and prior (non)sustained VT/VF consistently predict ventricular arrhythmias in all populations with ARVC.
Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmogenic right ventricular cardiomyopathy; Arrhythmogenic right ventricular dysplasia/cardiomyopathy; Meta-analysis; Prognosis; Risk stratification; Sudden cardiac death; Systematic review; Ventricular arrhythmias

Mesh:

Year:  2018        PMID: 29408436     DOI: 10.1016/j.hrthm.2018.01.031

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  26 in total

1.  A novel desmin mutation causing severe left ventricular arrhythmogenic cardiomyopathy/dysplasia.

Authors:  George Bazoukis; Konstantinos P Letsas; Yunlong Xia; Gary Tse; Ka Hou Christien Li
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  [Genetic testing to prevent sudden cardiac death].

Authors:  B Stallmeyer; S Dittmann; E Schulze-Bahr
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

3.  Clinical and genetic features of arrhythmogenic cardiomyopathy: diagnosis, management and the heart failure perspective.

Authors:  Matteo Castrichini; Ramone Eldemire; Daniel W Groves; Matthew Rg Taylor; Shelley Miyamoto; Luisa Mestroni
Journal:  Prog Pediatr Cardiol       Date:  2021-11-02

4.  Genetic Variant Score and Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Plakophilin-2 Mutation Carriers.

Authors:  Anneli Svensson; Pyotr G Platonov; Kristina H Haugaa; Wojciech Zareba; Henrik Kjærulf Jensen; Henning Bundgaard; Thomas Gilljam; Trine Madsen; Jim Hansen; Lars A Dejgaard; Lars O Karlsson; Anna Gréen; Bronislava Polonsky; Thor Edvardsen; Jesper Hastrup Svendsen; Cecilia Gunnarsson
Journal:  Cardiology       Date:  2021-09-01       Impact factor: 1.869

5.  New Variant in Placophilin-2 Gene Causing Arrhythmogenic Myocardiopathy.

Authors:  Fiama Caimi-Martinez; Guido Antoniutti; Rocio Blanco; Bernardo García de la Villa; Nelson Alvarenga; Nancy Govea-Callizo; Laura Torres-Juan; Damián Heine-Suñer; Jordi Rosell-Andreo; David Crémer Luengos; Jorge Alvarez-Rubio; Tomás Ripoll-Vera
Journal:  Genes (Basel)       Date:  2022-04-27       Impact factor: 4.141

6.  Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

Authors:  Lauren Eberly; Lohit Garg; Mahesh Vidula; Nosheen Reza; Sheela Krishnan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-09-18

7.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Eric D Smith; Neal K Lakdawala; Nikolaos Papoutsidakis; Gregory Aubert; Andrea Mazzanti; Anthony C McCanta; Prachi P Agarwal; Patricia Arscott; Lisa M Dellefave-Castillo; Esther E Vorovich; Kavitha Nutakki; Lisa D Wilsbacher; Silvia G Priori; Daniel L Jacoby; Elizabeth M McNally; Adam S Helms
Journal:  Circulation       Date:  2020-05-06       Impact factor: 29.690

Review 8.  Molecular mechanisms of arrhythmogenic cardiomyopathy.

Authors:  Karyn M Austin; Michael A Trembley; Stephanie F Chandler; Stephen P Sanders; Jeffrey E Saffitz; Dominic J Abrams; William T Pu
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

Review 9.  Emerging concepts in arrhythmogenic dilated cardiomyopathy.

Authors:  Thomas Zegkos; Theofilos Panagiotidis; Despoina Parcharidou; Georgios Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

10.  Right Ventricular Strain Predicts Structural Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Nitin Malik; Sithu Win; Cynthia A James; Shelby Kutty; Monica Mukherjee; Nisha A Gilotra; Crystal Tichnell; Brittney Murray; Julia Agafonova; Harikrishna Tandri; Hugh Calkins; Allison G Hays
Journal:  J Am Heart Assoc       Date:  2020-04-03       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.